PT1750713E - Utilização de imatinib para tratar distúrbios e infeções virais do fígado - Google Patents
Utilização de imatinib para tratar distúrbios e infeções virais do fígadoInfo
- Publication number
- PT1750713E PT1750713E PT57528614T PT05752861T PT1750713E PT 1750713 E PT1750713 E PT 1750713E PT 57528614 T PT57528614 T PT 57528614T PT 05752861 T PT05752861 T PT 05752861T PT 1750713 E PT1750713 E PT 1750713E
- Authority
- PT
- Portugal
- Prior art keywords
- imatinib
- viral infections
- liver disorders
- treat liver
- treat
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/21—Interferons [IFN]
- A61K38/212—IFN-alpha
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
- A61P31/22—Antivirals for DNA viruses for herpes viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Virology (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Zoology (AREA)
- Immunology (AREA)
- Biotechnology (AREA)
- Pulmonology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines Containing Plant Substances (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US57657304P | 2004-06-04 | 2004-06-04 |
Publications (1)
Publication Number | Publication Date |
---|---|
PT1750713E true PT1750713E (pt) | 2013-01-25 |
Family
ID=35462722
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PT57528614T PT1750713E (pt) | 2004-06-04 | 2005-06-03 | Utilização de imatinib para tratar distúrbios e infeções virais do fígado |
Country Status (25)
Country | Link |
---|---|
US (1) | US8293745B2 (pt) |
EP (1) | EP1750713B1 (pt) |
JP (1) | JP5015769B2 (pt) |
KR (1) | KR101246863B1 (pt) |
CN (2) | CN1976709A (pt) |
AP (1) | AP2715A (pt) |
AR (1) | AR049141A1 (pt) |
AU (1) | AU2005249159A1 (pt) |
BR (1) | BRPI0511805A (pt) |
CA (1) | CA2568671A1 (pt) |
DK (1) | DK1750713T3 (pt) |
EA (1) | EA013813B1 (pt) |
EC (1) | ECSP055833A (pt) |
ES (1) | ES2397830T3 (pt) |
IL (1) | IL179796A0 (pt) |
MA (1) | MA28840B1 (pt) |
MX (1) | MXPA06014063A (pt) |
MY (1) | MY148676A (pt) |
PE (1) | PE20060399A1 (pt) |
PL (1) | PL1750713T3 (pt) |
PT (1) | PT1750713E (pt) |
TN (1) | TNSN06398A1 (pt) |
TW (1) | TWI393565B (pt) |
UY (1) | UY28942A1 (pt) |
WO (1) | WO2005117885A1 (pt) |
Families Citing this family (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP2260849A1 (en) * | 2004-01-21 | 2010-12-15 | Emory University | Compositions and methods of use for tyrosine kinase inhibitors to treat pathogenic infection |
AR056347A1 (es) | 2005-05-12 | 2007-10-03 | Tibotec Pharm Ltd | Uso de compuestos de pteridina para fabricar medicamentos y composiciones farmaceuticas |
CA2824301C (en) | 2005-11-25 | 2016-01-12 | Novartis Ag | F, g, h, i and k crystal forms of imatinib mesylate |
JP5520479B2 (ja) * | 2006-02-20 | 2014-06-11 | コニカミノルタ株式会社 | 有機エレクトロルミネッセンス素子、白色発光素子、及び照明装置 |
US9987277B2 (en) | 2006-10-04 | 2018-06-05 | Janssen Sciences Ireland Uc | Carboxamide 4-[(4-pyridyl)amino] pryimidines for the treatment of hepatitis C |
US8435510B2 (en) | 2007-08-08 | 2013-05-07 | Sutter West Bay Hospitals | Platelet derived growth factor receptor supports cytomegalovirus infectivity |
FR2923160B1 (fr) | 2007-11-02 | 2013-07-26 | Pasteur Institut | Composes destines a prevenir ou traiter une infection virale. |
WO2010034670A2 (en) * | 2008-09-26 | 2010-04-01 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Host cell kinases as targets for antiviral therapies against hcv infection |
CA2744947A1 (en) * | 2008-12-19 | 2010-10-28 | The Regents Of The University Of California | Use of epidermal growth factor inhibitors in the treatment of viral infection |
WO2012118599A1 (en) * | 2011-02-28 | 2012-09-07 | Emory University | C-abl tyrosine kinase inhibitors useful for inhibiting filovirus replication |
WO2013024158A1 (en) * | 2011-08-17 | 2013-02-21 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Combinations of protein kinase inhibitors and interferons or of protein kinase inhibitors and direct acting antivirals for the treatment and the prevention of hcv infection |
KR101386697B1 (ko) | 2012-06-18 | 2014-04-18 | 아주대학교산학협력단 | 이매티닙 또는 이의 약학적으로 허용되는 염을 유효성분으로 포함하는 혈관 투과성 관련 질환의 치료 또는 예방용 조성물 |
CA2886744A1 (en) * | 2012-10-04 | 2014-04-10 | Inhibikase Therapeutics, Inc. | Imatinib derivatives, their preparation and use to treat cancer and bacterial and viral infections |
WO2017083971A1 (en) * | 2015-11-16 | 2017-05-26 | University Of Manitoba | Compositions and methods for treatment of influenza |
CN111481671A (zh) * | 2020-05-26 | 2020-08-04 | 华中科技大学同济医学院附属协和医院 | 酪氨酸激酶抑制剂在制备系统性红斑狼疮脑病药物中的应用 |
Family Cites Families (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5443965A (en) * | 1990-04-06 | 1995-08-22 | Genelabs Incorporated | Hepatitis C virus epitopes |
US6472373B1 (en) * | 1997-09-21 | 2002-10-29 | Schering Corporation | Combination therapy for eradicating detectable HCV-RNA in antiviral treatment naive patients having chronic hepatitis C infection |
JP2004520007A (ja) * | 2000-08-01 | 2004-07-08 | オーソ−マクニール・フアーマシユーチカル・インコーポレーテツド | Kshv感染の遺伝子発現プロフィール及びkshv感染を処置する方法 |
CA2446864C (en) | 2001-05-16 | 2011-02-15 | Vertex Pharmaceuticals Incorporated | Inhibitors of src and other protein kinases |
WO2003002109A2 (en) * | 2001-06-29 | 2003-01-09 | Ab Science | Use of tyrosine kinase inhibitors for treating autoimmune diseases |
IL165262A0 (en) * | 2002-05-23 | 2005-12-18 | Cytopia Pty Ltd | Kinase inhibitors |
US7064127B2 (en) * | 2003-12-19 | 2006-06-20 | Mount Sinai School Of Medicine Of New York University | Treatment of hepatic fibrosis with imatinib mesylate |
EP2260849A1 (en) * | 2004-01-21 | 2010-12-15 | Emory University | Compositions and methods of use for tyrosine kinase inhibitors to treat pathogenic infection |
-
2005
- 2005-06-03 JP JP2007513637A patent/JP5015769B2/ja not_active Expired - Fee Related
- 2005-06-03 UY UY28942A patent/UY28942A1/es not_active Application Discontinuation
- 2005-06-03 EA EA200602289A patent/EA013813B1/ru not_active IP Right Cessation
- 2005-06-03 CN CNA200580022154XA patent/CN1976709A/zh active Pending
- 2005-06-03 PE PE2005000626A patent/PE20060399A1/es not_active Application Discontinuation
- 2005-06-03 EP EP05752861A patent/EP1750713B1/en active Active
- 2005-06-03 TW TW094118426A patent/TWI393565B/zh not_active IP Right Cessation
- 2005-06-03 PT PT57528614T patent/PT1750713E/pt unknown
- 2005-06-03 AU AU2005249159A patent/AU2005249159A1/en not_active Abandoned
- 2005-06-03 EC EC2005005833A patent/ECSP055833A/es unknown
- 2005-06-03 PL PL05752861T patent/PL1750713T3/pl unknown
- 2005-06-03 DK DK05752861.4T patent/DK1750713T3/da active
- 2005-06-03 CN CN2011100317357A patent/CN102085202A/zh active Pending
- 2005-06-03 MY MYPI20052542A patent/MY148676A/en unknown
- 2005-06-03 CA CA002568671A patent/CA2568671A1/en not_active Abandoned
- 2005-06-03 MX MXPA06014063A patent/MXPA06014063A/es active IP Right Grant
- 2005-06-03 BR BRPI0511805-0A patent/BRPI0511805A/pt not_active IP Right Cessation
- 2005-06-03 WO PCT/CA2005/000869 patent/WO2005117885A1/en active Application Filing
- 2005-06-03 KR KR1020077000191A patent/KR101246863B1/ko not_active IP Right Cessation
- 2005-06-03 AP AP2006003863A patent/AP2715A/xx active
- 2005-06-03 ES ES05752861T patent/ES2397830T3/es active Active
- 2005-06-06 AR ARP050102296A patent/AR049141A1/es unknown
- 2005-09-14 US US11/228,982 patent/US8293745B2/en not_active Expired - Fee Related
-
2006
- 2006-12-03 IL IL179796A patent/IL179796A0/en unknown
- 2006-12-04 TN TNP2006000398A patent/TNSN06398A1/en unknown
-
2007
- 2007-01-02 MA MA29603A patent/MA28840B1/fr unknown
Also Published As
Publication number | Publication date |
---|---|
TW200602059A (en) | 2006-01-16 |
EA013813B1 (ru) | 2010-08-30 |
WO2005117885A1 (en) | 2005-12-15 |
AU2005249159A1 (en) | 2005-12-15 |
PL1750713T3 (pl) | 2013-04-30 |
MXPA06014063A (es) | 2007-04-25 |
US20060275260A1 (en) | 2006-12-07 |
BRPI0511805A (pt) | 2008-01-15 |
MY148676A (en) | 2013-05-31 |
MA28840B1 (fr) | 2007-09-03 |
ES2397830T3 (es) | 2013-03-11 |
DK1750713T3 (da) | 2013-02-11 |
EP1750713A1 (en) | 2007-02-14 |
IL179796A0 (en) | 2007-05-15 |
AP2006003863A0 (en) | 2006-12-31 |
JP2008501646A (ja) | 2008-01-24 |
ECSP055833A (es) | 2005-09-20 |
PE20060399A1 (es) | 2006-07-06 |
UY28942A1 (es) | 2005-11-30 |
CA2568671A1 (en) | 2005-12-15 |
CN1976709A (zh) | 2007-06-06 |
AP2715A (en) | 2013-07-31 |
EP1750713A4 (en) | 2010-09-15 |
JP5015769B2 (ja) | 2012-08-29 |
TNSN06398A1 (en) | 2008-02-22 |
US8293745B2 (en) | 2012-10-23 |
CN102085202A (zh) | 2011-06-08 |
EP1750713B1 (en) | 2012-10-17 |
TWI393565B (zh) | 2013-04-21 |
KR101246863B1 (ko) | 2013-03-25 |
KR20070051832A (ko) | 2007-05-18 |
AR049141A1 (es) | 2006-06-28 |
EA200602289A1 (ru) | 2007-04-27 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
IL179796A0 (en) | Use of imatinib to treat liver disorders and viral infections | |
IL176486A0 (en) | Azabenzofuran substituted thioureas as inhibtitors of viral replication | |
HK1126212A1 (en) | Heterocyclic compounds and uses thereof in the treatment of sexual disorders | |
ZA200607433B (en) | Methods and compositions for the treatment of gastroin-testinal disorders | |
EP1755661A4 (en) | USE OF GELSOLINE FOR THE TREATMENT OF INFECTIONS | |
EP1874286A4 (en) | METHOD AND COMPOSITIONS FOR TREATING ANXIETY STATE | |
IL185914A0 (en) | Pyrimidine compounds and methods of use | |
IL195272A0 (en) | Methods and compositions for the treatment of viral infections | |
IL189364A0 (en) | Estrogen compositions and therapeutic methods of use thereof | |
ZA200901523B (en) | Use of extracts for the treatment of viral disorders | |
IL182222A0 (en) | Treatment of bipolar disorders and associated symptoms | |
IL182785A0 (en) | Particles for treatment of pulmonary infection | |
BRPI0809272A2 (pt) | Compostos de biaril e biheteroaril no tratamento de distúrbios do ferro | |
EP1786265A4 (en) | NEW COMPOSITIONS AND PROCESSING METHODS | |
GB2410919B (en) | Improvements in or relating to the treatment of waste | |
IL186325A0 (en) | Tizanidine compositions and methods of treatment using the compositions | |
GB0329254D0 (en) | Treatment of viral infections | |
GB2411354B (en) | Use of Scutellaria for the treatment of viral infections | |
EP1765331A4 (en) | METHODS AND COMPOSITIONS FOR THE TREATMENT OF PULMONARY DISEASES | |
IL178970A0 (en) | Haplotype markers and methods of using the same to determine response to treatment | |
ZA200904068B (en) | Anti-tsg101 antibodies and their uses for treatment of viral infections | |
GB0329958D0 (en) | Treatment of viral infections | |
PT2572724T (pt) | Tratamento de fibroses e doenças hepáticas | |
GB0504333D0 (en) | Treatment of cytokine dysregulation | |
EP1776140A4 (en) | METHOD FOR INHIBITING VIRAL REPLICATION |